Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ7174MR)

This product GTTS-WQ7174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.

Specifications
Product type	mRNA
Modified bases	5-Methoxy-UTP
5' Cap	Cap 1
Species	Chimeric
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7174MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15871MR	IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	XmAb5871
GTTS-WQ6031MR	IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	CNTO 1275
GTTS-WQ7259MR	IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	FP3 protein
GTTS-WQ6884MR	IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	E-6011
GTTS-WQ9474MR	IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	IPH-5401
GTTS-WQ12490MR	IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	NN-8226
GTTS-WQ10278MR	IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	LFG 316
GTTS-WQ4349MR	IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	BIW-8405

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST